Other AreasPhenylpropanolamine (PPA)

Frequently Asked Questions

Why choose Early, Ludwick, Sweeney & Strauss to handle your PPA case?

Early, Ludwick, Sweeney & Strauss (ELSS) is a multi-state, law firm with offices in New York City and New Haven, Connecticut. ELSS is nationally recognized and concentrates on toxic torts including asbestos, fen-phen, lead paint, and others.

ELSS is currently handling cases of persons who may have been injured as a result of taking phenylpropanolamine (PPA). Our staff has extensive experience in pharmaceutical litigation involving fen-phen, Rezulin, Propulsid, Ephedra and other toxic medications. We can help you determine whether you or your loved one has a products liability claim against the manufacturers of drugs containing phenylpropanolamine (PPA).

What action did the FDA take?

On November 6, 2000, the FDA issued a Public Health Advisory in which it stated: "the FDA recommends that consumers not use any products that contain phenylpropanolamine [PPA]."

What products contained Phenylpropanolamine [PPA]?

Many popular over-the-counter appetite suppressants (such as Accutrim and Dexatrim) and cough/cold medications (such as Alka-Seltzer Plus, Comtrex, Dimetapp, Triaminic) contained phenylpropanolamine [PPA]. In the case of any medication, read the label for a listing of the active and inactive ingredients and to determine whether or not phenylpropanolamine [PPA] is included. For a fuller list of products, click here.

Why did the FDA issue this Advisory?

The FDA based its Advisory on "a recent study [that] reported that taking phenylpropanolamine [PPA] increases the risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in womenAlthough the risk of hemorrhagic stroke is very low, FDA has significant concerns because of the seriousness of a stroke and the inability to predict who is at risk."